stockrow
Friday 6 November 2026
Export CLRB’s income statement to Excel — free account
Cellectar Biosciences, Inc.
CLRB Healthcare Biotechnology
- EPS
- +83.2%
- Free cash flow
- −17.5%
Quarter to June 2026, against a year earlier
1.24
0.09
+7.83%
Follow CLRB
Alert me
Cellectar Biosciences, Inc. (CLRB) P/E ratio
Cellectar Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1.8× (October 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 1.8×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TVRD Tvardi Therapeutics, Inc. compare | n/m |
| HIND Vyome Holdings, Inc. compare | n/m |
| BIVI BioVie Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. | n/m |
| LPCN Lipocine Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.1× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)